Financial Data and Key Metrics Changes - The company reported a significant improvement in normalized earnings before tax, which increased by 61% year on year, marking the strongest quarterly normalized EBT result in two years [5][19] - Gross margin percentage improved by 4.1 percentage points, with gross margin dollars up 13.4%, indicating effective cost management and efficiency programs [6][18] - The net loss after tax reduced by $32.5 million to $15.6 million, showing consistent improvement throughout the year [17] Business Line Data and Key Metrics Changes - The freight and fuel business experienced a turnaround, with normalized earnings loss improving by 90% year on year, moving to a positive result in Q4 FY '25 [11] - Warehousing faced ongoing challenges due to increased industry capacity and aggressive pricing tactics, leading to a need for a reset in the business [12][13] - The specialist business performed well, particularly in infrastructure projects, with a healthy pipeline for the next two years [14] Market Data and Key Metrics Changes - The trading environment in FY '25 was challenging due to ongoing economic headwinds, low business and consumer confidence, and cost of living pressures [8] - Increased competitor activity and aggressive pricing were noted, particularly in the warehousing sector, leading to a glut in capacity [9][12] - Despite these challenges, there are signs of improving sentiment among partners, indicating potential recovery [10] Company Strategy and Development Direction - The company is focused on transitioning from cost reduction to value creation as part of its Accelerate transformation program, which has one year remaining [6][22] - The New Horizons roadmap aims to establish the company as the preferred logistics provider in New Zealand by FY '28 [21] - Priorities include improving performance in warehousing, enhancing customer retention, and investing in technology for data-driven decisions [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the uncertainty in the timing and speed of economic recovery but expressed confidence in the company's positioning and readiness for growth [23][24] - The focus on gross margin improvements is expected to provide a stronger foundation for future earnings growth [24] - Management is optimistic about returning to positive normalized EBT in FY '26 [24] Other Important Information - The company has established a new funding partnership and extended its bank facility through August 2026, ensuring adequate capital for operations and growth [19][20] - A significant reduction in operating expenses of $27 million was achieved, with labor savings of approximately $15 million [17][18] Q&A Session Summary Question: Will there be any months in FY '26 with positive net profit after tax? - Management could not specify exact months but indicated a clear plan and forecast, noting that the freight and logistics sector typically ramps up after slower months [25] Question: Is a capital raise likely given the erosion of equity and uncertain net profit? - Management stated that while they expect positive EBT, they are focused on ensuring adequate capital for business operations and growth [26][27] Question: What is the EBT range guidance for the coming year? - Management refrained from providing specific guidance due to economic uncertainty but confirmed a return to positive EBT in FY '26 [28] Question: Can management provide clarity on core freight revenue and margin after the realignment of fuel services? - Management declined to share specific details on core freight results, citing confidentiality regarding customer data [29][30]

Mesoblast (MESO) H2 2025 Earnings Call August 28, 2025 06:30 PM ET Company ParticipantsSilviu Itescu - Founder, CEO & MDAndrew Chaponnel - Interim CFOMarcelo Santoro - Chief Commercial OfficerConference Call ParticipantsEdward Tenthoff - MD & Senior Research AnalystOlivia Brayer - Director & Senior Biotech AnalystElyse Shapiro - Senior Analyst - HealthcareMichael Okunewitch - Senior Research Analyst - BiotechnologyJohn Hester - Senior AnalystOperatorHello, and welcome to the Mesoblast Financial Results for ...

Financial Data and Key Metrics Changes - Revenue from cell therapy products increased to $17.2 million, up 191% from the prior year, driven by the successful launch of Ryoncil [12][15] - Net operating cash spend for the year was $50 million, consistent with the prior year, despite investments in commercial team build-out and product launch activities [13][15] - Cash on hand as of June 30 was $162 million [13] Business Line Data and Key Metrics Changes - Ryoncil generated $13.2 million in gross sales and $11.3 million in net sales after a 14.6% gross to net adjustment [12] - Cost of revenues related to product sales was $1.2 million, representing 10% of net product sales, resulting in a gross margin of 90% [15] - Selling, general, and administrative expenses rose to $39.3 million, an increase of $14.3 million from FY 2024, primarily due to the commercial team build-out and product launch [15] Market Data and Key Metrics Changes - The addressable market for Ryoncil in pediatric acute graft versus host disease (GVHD) is approximately $1 billion, with potential label extensions in adults and inflammatory bowel disease exceeding $5 billion [8] - The addressable market for chronic low back pain and heart failure with reduced ejection fraction is each over $10 billion [8] Company Strategy and Development Direction - The company aims to expand Ryoncil's label to include adult patients with GVHD and other inflammatory conditions, leveraging existing pediatric treatment centers [24][25] - Plans to initiate pivotal studies for Ryoncil in inflammatory bowel disease and chronic low back pain, targeting significant unmet medical needs [40][41] - The company is transitioning from an R&D-focused organization to a commercial biotech entity, emphasizing the importance of building a robust commercial infrastructure [87] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the successful launch of Ryoncil and the potential for continued revenue growth as more treatment centers are onboarded [76] - The company is focused on addressing the opioid crisis by providing alternatives for chronic pain management through its RexLemistroCell product [32] - Management highlighted the importance of FDA alignment for accelerated approval pathways and ongoing discussions regarding trial designs for heart failure and inflammatory bowel disease [77] Other Important Information - Ryoncil became commercially available on March 28, 2025, shortly after receiving FDA approval in December 2024 [10] - The company has onboarded 32 transplant centers in the U.S. and aims to reach 45 centers that account for 80% of pediatric bone marrow transplants [10][11] - Medicaid coverage for Ryoncil was mandated on July 1, expanding access to over 250 million lives in the U.S. [11][82] Q&A Session Summary Question: Timeline for adult GVHD label extension - Management expects to commence an adult acute GVHD trial this quarter, aiming to add Ryoncil on top of existing second-line agents [45][46] Question: Update on Phase III chronic lower back pain trial - Enrollment is progressing well with almost 40 sites, and management is optimistic about outcomes similar to previous trials [48][50] Question: Monthly treatment kits administered and inventory dynamics - Treatment kits are stocked based on weight bands, and inventory is replenished as children are treated [55][56] Question: Gross to net dynamics and adult GVHD trial design - Management expects gross to net adjustments to remain flat and will target patients on Jakafi for the adult trial [59][60] Question: Details on adult study and trial design - The trial will focus on patients with severe disease on Jakafi, aiming to increase responder rates significantly [64][65] Question: Timeline for inflammatory bowel disease trials - A KOL group is designing the trial, with updates expected this quarter [68] Question: Distribution of initial sales and revenue trajectory - It is too early to project future sales, but management expects continued strengthening of sales as infrastructure is built [73][76] Question: Market access progress - The company has engaged with over 97 payers, achieving coverage for over 250 million lives, with Medicaid coverage in place across all states [81][82]

The Gap (GAP) Q2 2026 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsWhitney Notaro - VP & Head - IRRichard Dickson - CEO, President & DirectorKatrina O’Connell - EVP & CFOAlex Straton - MD - Equity ResearchMarni Shapiro - Managing PartnerBrooke Roach - VP - Equity ResearchLorraine Hutchinson - Managing DirectorDana Telsey - CEO & Chief Research OfficerConference Call ParticipantsMatt Boss - Equity Research AnalystIke Boruchow - MD & Senior Analyst - Retailing, Specialty Softlines & E-commerc ...

Elastic (ESTC) Q1 2026 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsEric Prengel - Global VP - FinanceAshutosh Kulkarni - CEO & Executive DirectorNavam Welihinda - CFORaimo Lenschow - Managing DirectorSanjit Singh - Executive DirectorKash Rangan - Managing DirectorBrian Essex - Executive DirectorBrent Thill - MD & Tech Sector Leader - Software & Internet ResearchConference Call ParticipantsMatthew Hedberg - Software AnalystGeorge McGreehan - Equity Research AnalystRob Owens - MD & Senior Re ...

IREN (IREN) Q4 2025 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsMike Power - VP - IRDaniel Roberts - Co-Founder & Co-CEOBelinda Nucifora - CFOAnthony Lewis - Chief Capital OfficerKent Draper - Chief Commercial OfficerJoseph Vafi - MD - Equity ResearchCharlie Pearce - Equity Research AssociateBrett Knoblauch - Managing DirectorStephen Glagola - Director - TMT Equity ResearchBenjamin Sommers - Equity Research AssociateConference Call ParticipantsPaul Golding - US Senior Payments & Lifestyle ...

Autodesk (ADSK) Q2 2026 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsSimon Mays-Smith - VP - IRAndrew Anagnost - President, CEO & DirectorJanesh Moorjani - EVP & CFOSaket Kalia - Managing DirectorAdam Borg - MD - Enterprise SoftwareJay Vleeschhouwer - Managing DirectorElizabeth Porter - Executive Director - Equity ResearchJoshua Tilton - DirectorSiti Panigrahi - Managing DirectorKoji Ikeda - Director - Enterprise Software Equity ResearchConference Call ParticipantsJason Celino - MD & Equity ...

Affirm (AFRM) Q4 2025 Earnings Call August 28, 2025 05:00 PM ET Company ParticipantsZane Keller - Head - IRMax Levchin - Director, Founder & CEOAdam Frisch - Senior Managing Director - EquitiesRob O’Hare - CFOWill Nance - Vice PresidentMichael Linford - COOAdib Choudhury - Senior Equity Research AssociateJohn Hecht - Managing DirectorJames Faucette - Managing DirectorReggie Smith - Executive Director - Equity ResearchHarry Bartlett - VP - Equity ResearchGiuliano Bologna - Managing DirectorConference Call Pa ...

Autodesk (ADSK) Q2 2026 Earnings Call August 28, 2025 05:00 PM ET Speaker0Thank you for standing by, and welcome to Autodesk Second Quarter and Full Year Fiscal twenty twenty six Earnings Conference Call. At this time, all participants are in a listen only mode. After the speaker presentation, there will be a question and answer session. I would now like to hand the call over to Simon May Smith, Vice President, Investor Relations. Please go ahead.Speaker1Thanks, operator, and good afternoon. Thank you for j ...

Financial Data and Key Metrics Changes - The company reported total revenue of $415 million for Q1 2026, representing a 20% year-over-year growth and an 18% growth on a constant currency basis [27] - Sales-led subscription revenue, excluding monthly Elastic Cloud, was $339 million, growing 22% as reported and 20% on a constant currency basis [27] - Non-GAAP operating margin was 16%, with a gross margin of 79% [32] Business Line Data and Key Metrics Changes - Subscription revenue growth was driven by both cloud and self-managed offerings, with strong performance across all solution areas [28] - The company ended the quarter with over 1,550 customers spending more than $100,000 annually, indicating strong enterprise adoption [7] - The number of Elastic Cloud customers using Gen AI use cases exceeded 2,200, with over 330 customers spending $100,000 or more annually [12] Market Data and Key Metrics Changes - In the U.S. Public sector, signs of stabilization were noted, with a strategic agreement signed with the U.S. General Services Administration [9] - The company reported strong customer commitments and competitive success in the security segment, with one-third of new and expansion deals coming from competitive displacements [28][51] Company Strategy and Development Direction - The company is focused on leveraging its Search AI platform to drive growth in Gen AI and platform consolidation across various industries [23] - The strategic alignment of the sales team towards expanding enterprise accounts and high-potential mid-market customers is proving effective [10] - The introduction of new capabilities, such as the Elastic AI SOC engine (EASE), aims to enhance threat detection and drive further adoption [28][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong execution and market position, despite operating in a complex macro environment [34] - The company raised its fiscal 2026 revenue guidance, reflecting better-than-expected macro conditions and strong demand for its solutions [34] - Management highlighted the importance of search relevance and context in the AI era, positioning the company as a leader in data retrieval and context engineering [15][101] Other Important Information - The company achieved an adjusted free cash flow margin of 28% in Q1, with expectations to maintain and expand this margin over time [33] - The current remaining performance obligations (CRPO) grew 18% year-over-year, reaching approximately $956 million [30] Q&A Session Summary Question: Customer spend uplift related to AI usage - Management noted that as customers utilize AI applications, workloads tend to be more compute-intensive, leading to increased overall consumption [42] Question: Impact of price increases on guidance - The price increase implemented in May is expected to provide a year-over-year benefit, but the majority of growth is attributed to performance rather than price [46] Question: Growth mix across business segments - Management indicated strong performance across all solution areas, with Gen AI driving growth in search, security, and observability [50] Question: Predictability of the business model - Management expressed confidence in the predictability of sales-led subscription growth, noting strong execution and consistency in performance [52] Question: Competitive displacements in security - Management highlighted a growing trend of customers recognizing security as a data problem, leading to increased migrations to the company's platform [58] Question: Federal business stabilization - Management confirmed stabilization in the U.S. Public sector, with expectations for continued execution and alignment with customer needs [90][94]